October 7, 2015 Off

Horizon In-licenses Oncology Programme from Servier and Enters Option Agreement

By Dino Mustafić

Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .

October 7, 2015 Off

Sanofi: New Analysis on Relapsing Multiple Sclerosis

By Dino Mustafić

Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).